{
  "source": "PA-Notification-Carbaglu.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1224-8\nProgram Prior Authorization/Notification\nMedication Carbaglu® (carglumic acid)\nP&T Approval Date 7/2017, 7/2018, 7/2019, 7/2020, 7/2021, 7/2022, 7/2023, 7/2024\nEffective Date 10/1/2024\n1. Background\nCarbaglu (carglumic acid) is a carbamoyl phosphate synthetase 1 (CPS 1) activator indicated in\npediatric and adult patients as maintenance therapy for the treatment of chronic\nhyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency, adjunctive therapy to\nstandard of care for the treatment of acute hyperammonemia due to NAGS deficiency, and\nadjunctive therapy to standard of care for the treatment of acute hyperammonemia due to\npropionic acidemia (PA) or methylmalonic acidemia (MMA).\nCoverage for Carbaglu will be provided for patients who meet the following criteria:\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Carbaglu will be approved based on the following criterion:\na. Diagnosis of hyperammonemia due to one of the following:\n(1) N-acetylglutamate synthase (NAGS) deficiency\n(2) Propionic acidemia (PA)\n(3) Methylmalonic acidemia (MMA)\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Carbaglu will be approved based on the following criterion:\na. Documentation of positive clinical response to Carbaglu therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n© 2024 UnitedHealthcare Services Inc.\n1\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limitations may be in place.\n4. References:\n1",
    "ory, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limitations may be in place.\n4. References:\n1. Carbaglu® [package insert], Lebanon, NJ: Recordati Rare Diseases Inc..; January 2024.\nProgram Prior Authorization/Notification – Carbaglu (carglumic acid)\nChange Control\n7/2017 New program.\n7/2018 Annual review with no change to coverage criteria. Updated reference.\n7/2019 Annual review with no change to coverage criteria.\n7/2020 Annual review with no change to coverage criteria. Updated\nbackground and reference.\n7/2021 Annual review. Added criteria for hyperammonemia due to propionic\nacidemia (PA) or methylmalonic acidemia (MMA). Updated\nbackground and reference.\n7/2022 Annual review with no change to coverage criteria. Added state\nmandate disclaimer.\n7/2023 Annual review. Updated reference.\n7/2024 Annual review with no changes to coverage criteria. Updated reference.\n© 2024 UnitedHealthcare Services Inc.\n2"
  ]
}